Patient Derived Xenograft Models Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Mice Models, Rat Models.); Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, Urological Tumor Models, Hematological Tumor Models, Other Tumor Models); Application (Preclinical Drug Development, Biomarker Analysis, Basic Cancer Research.); End-Users (Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Academic and Research Institutions.) and Geography
Patient-derived xenografts models are the models of cancer in which the cells or tissue are implanted from a patient's tumor into an immune-deficient mouse. PDX model offers the translational preclinical model for efficacy screening in cancer drug development for cancer, diabetes, infections, etc. PDX model has demonstrated advantages in biomarker growth and co-clinical studies. These models reflect the human patient population heterogeneity and diversity. PDX models have higher predictive values for clinical outcomes than any other model.
The patient-derived xenograft models market growth is driven mainly due to rising personalized medicine demand, growing research & development activities in the pharmaceutical industry, increasing burden of cancer, and continuous support for cancer research. Moreover, increasing demand for humanized PDX models and improved healthcare infrastructure is expected to propel the market growth. Due to the Covid-19 pandemic, the patient-derived xenograft models market experienced reduced productivity, reduced research and development activities, and disrupted clinical trials. In contrast, the high cost of models and required drugs and stringent guidelines considering ethical animal use in cancer research are factors that may restrain the growth of the patient-derived xenograft models market.
The "Patient Derived Xenograft Models Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of patient derived xenograft models market with detailed market segmentation by product type, tumor type, application and end-users. The patient derived xenograft models market are expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in patient derived xenograft models market and offers key trends and opportunities in the market.
The patient derived xenograft models market are segmented on the basis of product type, tumor type, application and end-users. On the basis of product type, the market is segmented into mice models, and rat models. On the basis of tumor type, the market is segmented as gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models. On the basis of application, the market is segmented into preclinical drug development, biomarker analysis, and basic cancer research. On the basis of end-users, the market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the patient derived xenograft models market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The patient derived xenograft models market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting patient derived xenograft models market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting the patient derived xenograft models market in these regions.
Get more information on this report :
The report covers key developments in the patient derived xenograft models market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from patient derived xenograft models market are anticipated to have lucrative growth opportunities in the future with the rising demand for patient derived xenograft models in the global market. Below mentioned is the list of few companies engaged in the patient derived xenograft models market.
The report also includes the profiles of key players in patient derived xenograft models market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
Crown Bioscience Inc.
Champions Oncology, Inc.
The Jackson Laboratory
Charles River Laboratories International, Inc.
EPO Berlin-Buch GmBH
Shanghai LIDE Biotech Co., Ltd
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Get more information on this report :
The List of Companies
1. Crown Bioscience Inc.
2. WuXi AppTec
3. Champions Oncology, Inc.
4. The Jackson Laboratory
6. Charles River Laboratories International, Inc.
7. EPO Berlin-Buch GmBH
8. Shanghai LIDE Biotech Co., Ltd